This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.
Heart Failure Foundation Course 2025: Managing renal function in people with heart failure with reduced ejection fraction (HFrEF)
ENTRESTO® (sacubitril/valsartan) is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF).1
For further information, please refer to the ENTRESTO Summary of Product Characteristics.
Click on the video below to find out more about renal function in patients with HFrEF.
HFrEF, heart failure with reduced ejection fraction.
Reference
ENTRESTO (sacubitril/valsartan) Summary of Product Characteristics.
UK | November 2025 | FA-11549144
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.